FLT1 and non-small cell lung carcinoma: The in‐house ELISA made by the combination of three peptide antigens derived from CD25, MUC1, and VEGFR1 could enhance the sensitivity for detection of natural anticancer antibodies that have a diagnostic value in screening of early‐stage NSCLC.